搜索结果31-40 的 26097 / Adenocarcinoma

  1. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    Patients with Barrett's Esophagus (BE) or Esophageal Adenocarcinoma (EAC) that are planned for Endoscopic Submucosal Dissection (ESD) treatment. Exclusion ...

  2. 神经科- 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...

  3. 脑肿瘤项目- 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...

  4. 神经科- 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...

  5. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    ... adenocarcinoma (PDAC). The potential complementary value of mutant KRAS and CA19-9 will also be evaluated. Pagination 临床研究. PrevPrevious Page · Go to page ...

  6. 壶腹癌- 诊断与治疗- 妙佑医疗国际

    Ampullary adenocarcinoma. National Comprehensive Cancer Network. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1511. Accessed Aug. 29 ...

  7. 肿瘤科（内科） - 临床试验- 妙佑医疗国际

    This study will evaluate if the sponge capsule device can accurately detect the presence of Barrett's Esophagus and prevalent dysplasia/adenocarcinoma ...

  8. 神经科- 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...

  9. 神经科- 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...

  10. 脑肿瘤项目- 临床试验- 妙佑医疗国际

    ... adenocarcinoma, (10) advanced, unresectable multiple myeloma. Also eligible are (11) up to 6 donors with triple negative breast cancer and (12) up to 6 ...